Nagaraja Sharma, MD
Cardiovascular Disease · Hudson, FLNPI 1275528804
Payments from drug & device makers
Across 229 payments — averaging $55.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$7K
- Boston Scientific$729
- Boehringer Ingelheim$648
- Edwards Lifesciences$599
- Medtronic$523
- Abbott$427
- plus $3K from 22 others
What the payments were for
- Travel & lodging$8186%
- Food & beverage$5,19641%
- Education$1001%
- Other$6,66752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $6,667 |
| Boston Scientific | 12 | $729 |
| Boehringer Ingelheim | 31 | $648 |
| Edwards Lifesciences | 4 | $599 |
| Medtronic | 9 | $523 |
| Abbott | 11 | $427 |
| Merck | 20 | $381 |
| Johnson & Johnson | 21 | $381 |
| Amarin Pharma, Inc. | 19 | $376 |
| Novartis | 16 | $263 |
| AstraZeneca | 16 | $251 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $177 |
| Astellas Pharma US Inc | 4 | $164 |
| E.r. Squibb & Sons, L.L.C. | 8 | $139 |
| Amgen | 3 | $139 |
| Pfizer | 6 | $117 |
| Novo Nordisk | 5 | $115 |
| Irhythm Technologies, Inc. | 4 | $85 |
| Scpharmaceuticals Inc. | 4 | $82 |
| Kowa Pharmaceuticals America, Inc. | 5 | $78 |
| Lexicon Pharmaceuticals, Inc. | 3 | $70 |
| Philips North America LLC | 2 | $70 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| Kestra Medical Technology Services, Inc. | 2 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Abiomed | 1 | $60 |
| Cardiovascular Systems Inc. | 2 | $32 |
| Medicomp Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,781 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 467 | $472,979 |
| EntrestoSacubitril/Valsartan | 105 | $123,221 |
| XareltoRivaroxaban | 64 | $86,640 |
| JardianceEmpagliflozin | 56 | $83,558 |
| FarxigaDapagliflozin Propanediol | 55 | $51,216 |
| VascepaIcosapent Ethyl | 37 | $29,113 |
| BrilintaTicagrelor | 18 | $21,898 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 321 | $14,286 |
| Metoprolol Succinate | 579 | $8,503 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 25 | $5,856 |
| ClopidogrelClopidogrel Bisulfate | 520 | $5,796 |
| SotalolSotalol Hcl | 189 | $5,474 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 350 | $5,129 |
| Amiodarone Hcl | 107 | $4,437 |
| Propafenone Hcl | 25 | $3,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $472,979467 claims |
| NovartisEntresto | $263 | $123,221105 claims |
| Johnson & JohnsonXarelto | $381 | $86,64064 claims |
| Boehringer IngelheimJardiance | $648 | $83,55856 claims |
| AstraZenecaFarxiga, Brilinta | $251 | $73,11473 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hudson
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.